To see the other types of publications on this topic, follow the link: Computer Associates International Inc.
Journal articles on the topic 'Computer Associates International Inc'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Computer Associates International Inc.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Valenti, Michael. "Can They Take the Heat?" Mechanical Engineering 122, no. 02 (February 1, 2000): 62–65. http://dx.doi.org/10.1115/1.2000-feb-4.
Full textAbstract:
This article describes that fire researchers apply old and new tests to assure that materials meet safety requirements. Baltimore-based Hughes Associates Inc., a fire research firm, uses standard tests and computer modeling, and, in some cases, will develop tests to ensure that new building products satisfy the safety requirements of existing building codes. Hughes Associates also facilitates contact between its client and the appropriate code-making organizations, whether local, state, federal in the case of governmental agencies, or internationally through its offices in Singapore and in Milan, Italy. The data derived from the small-scale tests are also used in flame spread computer modeling testing. These tests use a series of proprietary computer modeling programs to predict the behavior of the product’s flames—for example, how high the flames would reach, and how quickly they would spread. The development of amusement park attractions is driving fire testing to prove that these attractions meet the stringent public assembly provision in fire codes.
2
Jemaa, Skander, Samuel Tracy, Alessia Bottos, Alex de Crespigny, Thomas Bengtsson, Tina G. Nielsen, and Joseph N. Paulson. "Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients." Blood 136, Supplement 1 (November 5, 2020): 8–9. http://dx.doi.org/10.1182/blood-2020-134780.
Full textAbstract:
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for 30─40% of cases (Li, et al. Pathology 2017). Although rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) cures approximately 50─60% of patients, clinical outcomes remain poor for those with relapsed or refractory (R/R) disease (Liu and Barta. Am J Hematol 2019). Current prognostic models such as the International Prognostic Index (IPI) have suboptimal sensitivity and specificity to identify these patients at diagnosis. Models that combine biological, clinical and imaging markers may improve prognostication in DLBCL. Methods: We evaluated fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging features alongside clinical and biomarker data in modeling disease prognosis with a primary endpoint of investigator-assessed progression-free survival (PFS) for de novo DLBCL patients from the randomized phase III GOYA study (NCT01287741) comparing R-CHOP versus obinutuzumab (G)-CHOP. Imaging features were derived using a computer-vision modeling algorithm (Jemaa, et al. J Digit Imaging 2020), and included total and by-organ number and volume of lesions. The evaluable population (n=1286) was split into pre-defined training (n=964; PFS events=307) and holdout populations (n=322; PFS events=96). Baseline clinical and imaging features were dichotomized by median or a clinically relevant threshold, and screened with univariate Cox proportional hazard (PH) models (Figure A). Screened variables were further selected to construct a multivariate Cox PH model for risk prognosis utilizing a regularized LASSO Cox regression (Simon, et al. J Statistical Software 2011). Model performance was evaluated by area under the receiver operating characteristic curve (AUC) and C-index on the holdout population. Additional biomarker features were evaluated, including, BCL2 protein expression as determined by Ventana investigational-use only immunohistochemistry (IHC) assay, gene expression quantified by TruSeq® (Illumina) RNAseq, next generation sequencing-based genomic profiling using the FoundationOne HemeTM platform (F1H, Foundation Medicine Inc. [FMI]) and cell of origin (COO) by the Nanostring assay. Results: Total metabolic tumor volume (TMTV), total number of lesions, longest diameter of any lesion, number of kidney lesions, and number of liver lesions were selected as prognostic imaging factors for PFS in de novo DLBCL patients. Strong correlation was observed between corresponding volume and lesion number features, as expected, though collinearity appeared to otherwise be minimal (Figure B). Performance of the resulting model composed of these imaging variables alongside standard clinical features and treatment (AUC=0.66; C-Index=0.64) improved upon a model composed of IPI categories (AUC=0.60; C-Index=0.60). High risk, defined by log-hazard >0 was associated with reduced PFS (Figure C). High BCL2 expression by IHC (score >1) was prognostic for PFS independent of clinical and imaging features (HR, 2.02; CI: 1.36─2.98). High BCL2 was predictive of PFS in patients treated with G-CHOP over R-CHOP in de novo DLBCL patients (HR, 0.55; CI: 0.32─0.97) (Figure D). This trend held when adjusting for COO separate to imaging features. Mutational analysis using the FMI panel also indicated the additional prognostic value of BCL2 and TP53 single-nucleotide variants through selection by LASSO. Conclusions: Automated baseline imaging features and high BCL2 expression demonstrated prognostic value orthogonal to standard clinical features in predicting high-risk de novo DLBCL despite limitations imposed by sample size and multicollinearity among features. These findings support the integration of imaging, genomic and clinical factors in prognostic models to improve the identification of high-risk de novo DLBCL patients. Disclosures Jemaa: F. Hoffmann-La Roche: Current equity holder in publicly-traded company; Genentech, Inc.: Current Employment. Tracy:Genentech, Inc.: Current Employment; F. Hoffmann-La Roche: Current Employment, Current equity holder in publicly-traded company. Bottos:F. Hoffmann-La Roche: Current Employment, Current equity holder in private company. de Crespigny:Genentech, Inc.: Current Employment; F Hoffmann-La Roche: Current equity holder in publicly-traded company. Bengtsson:Genentech, Inc.: Current Employment; F Hoffmann-La Roche: Current equity holder in publicly-traded company. Nielsen:F. Hoffmann-La Roche: Current Employment, Current equity holder in publicly-traded company. Paulson:Genentech, Inc.: Current Employment; F. Hoffmann-Roche: Current equity holder in private company, Current equity holder in publicly-traded company.
3
Smith, Roger. "Mystech Associates, Inc. 7900 Sudley Road, Suite 500 Manassas, VA 22110." SIMULATION 59, no. 1 (July 1992): 46. http://dx.doi.org/10.1177/003754979205900111.
Full text
4
Pransky, Joanne. "The Pransky interview: Dr Nabil Simaan, Vanderbilt University Professor of Mechanical Engineering, Computer Science and Otolaryngology, Thought Leader in Medical Robotics." Industrial Robot: the international journal of robotics research and application 48, no. 4 (July 29, 2021): 473–77. http://dx.doi.org/10.1108/ir-03-2021-0053.
Full textAbstract:
Purpose The following article is a “Q&A interview” conducted by Joanne Pransky of Industrial Robot Journal as a method to impart the combined technological, business and personal experience of a prominent, robotic industry PhD and innovator regarding his pioneering efforts. The paper aims to discuss these issues. Design/methodology/approach The interviewee is Dr Nabil Simaan, Professor of Mechanical Engineering, Computer Science and Otolaryngology at Vanderbilt University. He is also director of Vanderbilt’s Advanced Robotics and Mechanism Applications Research Laboratory. In this interview, Simaan shares his unique perspective and approaches on his journey of trying to solve real-world problems in the medical robotics area. Findings Simaan received his BSc, MSc and PhD in mechanical engineering from the Technion – Israel Institute of Technology. He served as Postdoctoral Research Scientist in Computer Science at Johns Hopkins University. In 2005, he joined Columbia University, New York, NY, as an Assistant Professor of Mechanical Engineering until 2010, when he joined Vanderbilt. His current applied research interests include synthesis of novel robotic systems for surgical assistance in confined spaces with applications to minimally invasive surgery of the throat, natural orifice surgery, cochlear implant surgery and dexterous bimanual microsurgery. Theoretical aspects of his research include robot design and kinematics. Originality/value Dr Simaan is a leading pioneer on designing robotic systems and mechanisms for medical applications. Examples include technologies for snake robots licensed to Intuitive Surgical; technologies for micro-surgery of the retina, which led to the formation of AURIS Surgical Robotics; the insertable robotic effector platform (IREP) single-port surgery robot that served as the research prototype behind the Titan Medical Inc. Sport (Single Port Orifice Robotic Technology). Simaan received the NSF Career award for young investigators to design new algorithms and robots for safe interaction with the anatomy. He has served as the Editor for IEEE International Conference on Robotics and Automation, Associate Editor for IEEE Transactions on Robotics, Editorial Board Member of Robotica, Area Chair for Robotics Science and Systems and corresponding Co-chair for the IEEE Technical Committee on Surgical Robotics. In January 2020, he was bestowed the award of Institute of Electrical and Electronics Engineers (IEEE) Fellow for Robotics Advancements. At the end of 2020, he was named a top voice in health-care robotics by technology discovery platform InsightMonk and market intelligence firm BIS Research. Simaan holds 15 patents. A producer of human capital, his education goal is to achieve the best possible outcome with every student he works with.
5
Wuntakal, Rekha, Andreas John Papadopoulos, Stephen Attard Montalto, Milica Perovic, Michael Coutts, and Omer Devaja. "Location of Sentinel Lymph Node in Cervical Carcinoma and Factors Associated With Unilateral Detection." International Journal of Gynecologic Cancer 25, no. 9 (November 2015): 1663–68. http://dx.doi.org/10.1097/igc.0000000000000539.
Full textAbstract:
ObjectiveThe aims of this study were to assess locality of the sentinel lymph node (SLN) in cervical carcinoma and examine factors affecting bilateral SLN detection.MethodsThis was a retrospective review of SLN data (anatomical location, count and laterality) in patients with early-stage cervical cancer (International Federation of Gynecology and Obstetrics stage IA1 with lymphovascular space invasion to stage IIA) using intraoperative gamma probe and blue dye. The preoperative single-photon emission computed tomography with computed tomography was used to detect laterality, number of the SLNs, and rare locations. Patients were treated between January 2005 to January 2015 at the West Kent Gynaecological Oncology Centre, Maidstone Hospital, Maidstone, United Kingdom.ResultsA total of 132 women were investigated. The most common SLN location was the external iliac (38.6%) followed by obturator (25.3%) and internal iliac (23.6%) regions. A small percentage was identified in presacral (1.4%) and para-aortic regions (0.7%). Older age (P= 0.01) and an elevated body mass index (P= 0.03) were associated with decreased SLN count by preoperative single-photon emission computed tomography with computed tomography, and only age affected SLN count by gamma probe (P= 0.01). Initial surgery, large loop excision of the transformation zone, or cone biopsy of the cervix had no effect on SLN count. There was no difference observed in bilateral detection with respect to surgical approach (open: n = 48/laparoscopic: n = 84). However, older age was independently associated with a decrease in bilateral SLN detection (P= 0.003). In these patients who underwent unilateral full pelvic lymphadenectomy, all the nonsentinel nodes were negative.ConclusionsThe majority of SLNs were located in the external iliac, obturator, and internal iliac regions. Both older age and an elevated body mass index were associated with a reduced SLN count. Unilateral detection of SLN was independently associated with older age, which may be due to sclerosis in the lymphatic vessels or reduced perfusion in the pelvis in these women. If no SLN is detected on one side, the consensus is to perform a full pelvic lymphadenectomy on that side of the pelvis.
6
Kumar, Shaji, Ian W. Flinn, Paul G. Richardson, Parameswaran Hari, Natalie Scott Callander, Stephen J. Noga, A. Keith Stewart, et al. "Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study." Blood 116, no. 21 (November 19, 2010): 621. http://dx.doi.org/10.1182/blood.v116.21.621.621.
Full textAbstract:
Abstract Abstract 621 Background: Two- and three-drug regimens incorporating bortezomib (Velcade®, V), lenalidomide (Revlimid®, R), dexamethasone (D), or cyclophosphamide (C) have been shown to be effective and well tolerated in previously untreated multiple myeloma (MM). Combining all four drugs in a single regimen (VDCR) may further enhance efficacy. Published results from the phase 1 dose-escalation portion of the non-comparative, multi-center EVOLUTION study showed that the VDCR regimen was highly active and generally well tolerated (Kumar et al Leukemia 2010). Here we present updated results from the phase 2 portion of the trial, focusing on efficacy and safety of the VDCR, VDR, and VDC regimens. Methods: Previously untreated patients with measurable disease were randomized to one of four treatment groups receiving up to eight 21-d cycles of VDCR (V 1.3 mg/m2 d 1, 4, 8, 11; D 40 mg d 1, 8, 15; R 15 mg d 1–14; C 500 mg/m2 d 1, 8), VDR (VD as in VDCR but with R 25 mg d 1–14), VDC (VDC as in VDCR), or VDC-mod (as for VDC but with an additional dose of C on d 15) as induction therapy, followed by four 42-d maintenance cycles of V 1.3 mg/m2 (d 1, 8, 15, 22) (all treatment arms). Patients eligible for autologous stem cell transplant (SCT) could undergo stem cell mobilization any time after cycle 2 and SCT any time after cycle 4. The primary endpoint was the combined complete response (CR) + very good partial response (VGPR) rate; secondary endpoints included safety/tolerability, time to response, duration of response, progression-free survival, and rate of minimal residual disease (MRD) negativity. Responses were assessed according to International Myeloma Working Group (IMWG) uniform criteria using an automated computer algorithm. Adverse events (AEs) were graded using the CTCAE v3.0. Results: Patient characteristics were similar among the groups with respect to age, performance status, ISS stage, and proportion of patients with high-risk cytogenetic features. Patients received a median of 5, 6, 6, and 6 treatment cycles in the VDCR, VDR, VDC, and VDC-mod arms, respectively; 65%, 60%, 52%, and 47% of patients had dose reductions of any drug. In the VDCR, VDR, VDC, and VDC-mod arms, respectively, 52%, 62%, 58%, and 65% of patients completed treatment; 31%, 43%, 24%, and 41%, respectively, underwent SCT. In the phase 2 response-evaluable patients (n=132), all treatment regimens showed substantial efficacy, with CR+VGPR rates of 59% (VDCR), 50% (VDR), 41% (VDC), and 59% (VDC-mod) (Table) (includes pre-transplant responses only in SCT patients). Of MRD-assessed patients, 46% (21/46) of those who achieved CR (including sCR) or nCR were MRD-negative; 48% (10/21), 75% (9/12), 0% (0/7) and 33% (2/6) in the VDCR, VDR, VDC and VDC-mod arms, respectively. Median time to first response was similar across arms (range 1.6–1.8 months); median time to best response of CR+VGPR was 4.0 months (VDCR), 3.4 months (VDR), 5.1 months (VDC), and 3.1 months (VDC-mod). Median duration of response has not been reached in any arm to date. All treatment regimens were generally well tolerated. In the VDCR, VDR, VDC, and VDC-mod arms, at least one grade ≥3 AE was observed in 81%, 76%, 79%, and 88% of enrolled patients, respectively; serious AEs were experienced by 42%, 40%, 21%, and 41% of patients, and AEs resulting in study discontinuation were reported for 19%, 17%, 12%, and 6% of patients. The five most common all-grade AEs across all treatment groups were fatigue (range 47–67%), nausea (36–67%), constipation (40–62%), diarrhea NOS (42–65%), and neutropenia (19–52%). The incidence of grade ≥3 (grade ≥2) peripheral neuropathy (PN) was 13% (40%) in the VDCR arm, 14% (45%) VDR, 9% (48%) VDC, and 18% (41%) VDC-mod; there was no grade 4 PN. Rates of grade ≥3 neutropenia/thrombocytopenia were 42%/10% for VDCR, 7%/7% VDR, 36%/12% VDC, and 65%/18% VDC-mod. Conclusions: All regimens appear highly active and generally well tolerated in previously untreated MM patients. The four-drug combination did not result in a substantial increase in response rate and was associated with a modest increase in the incidence of hematologic toxicities. Continuous weekly C in the VDC regimen was associated with high response rates and rapid responses, comparable to the VDR and VDCR arms. Outcome data will be presented following longer follow-up. Disclosures: Kumar: Celgene: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Novartis: Research Funding; Genzyme: Consultancy, Research Funding; Cephalon: Research Funding; Bayer: Research Funding. Off Label Use: Lenalidomide for treatment of newly diagnosed myeloma. Flinn:Millennium Pharmaceuticals, Inc.: Research Funding. Richardson:Celgene, Millennium, Novartis, Johnson & Johnson: Membership on an entity's Board of Directors or advisory committees. Hari:Celgene: Research Funding. Callander:Millennium Pharmaceuticals, Inc.: Research Funding. Noga:Amgen: Honoraria, Research Funding, Speakers Bureau; Millennium: Consultancy, Honoraria, Research Funding, Speakers Bureau; Ortho-Centicor: Honoraria, Speakers Bureau; Cephalon: Honoraria, Research Funding, Speakers Bureau; Celgene: Honoraria, Research Funding, Speakers Bureau. Stewart:Millennium Pharmaceuticals, Inc.: Honoraria, Research Funding; Celgene: Honoraria. Rifkin:Millennium Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Speakers Bureau; Amgen: Speakers Bureau; Cephalon: Speakers Bureau; Dendreon: Speakers Bureau. Wolf:Millennium Pharmaceuticals: Consultancy, Honoraria, Speakers Bureau; Genentech and Multiple Myeloma Research: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Speakers Bureau; OrthoBiotech: Honoraria, Speakers Bureau; Celgene: Honoraria, Speakers Bureau. Estevam:Millennium Pharmaceuticals: Employment. Mulligan:Millennium Pharmaceuticals, Inc.: Employment. Shi:Millennium Pharmaceuticals: Employment. Webb:Millennium Pharmaceuticals: Employment.
7
Willis, J. B. "Three Little Companies — the Birth of a Major Australian Scientific Instrument Industry." Historical Records of Australian Science 14, no. 4 (2002): 403. http://dx.doi.org/10.1071/hr03007.
Full textAbstract:
The atomic absorption spectrometer revolutionized chemical analysis in the 1960s. Invented by Alan Walsh of the CSIRO Division of Chemical Physics, its manufacture in Australia began with three small Melbourne companies making the necessary optical, mechanical and electronic components. Subsequently, one of these companies, Techtron Pty Ltd, made a complete instrument and became a major supplier to the international market. Techtron expanded rapidly and in 1967 was sold to a large US company, Varian Associates Inc., which still operates as Varian Australia Pty Ltd and manufactures atomic absorption spectrometers and other scientific instruments at Mulgrave, Victoria.
8
Lee, Jeong Won, Seob Jeon, Seong Taek Mun, and Sang Mi Lee. "Prognostic Value of Fluorine-18 Fluorodeoxyglucose Uptake of Bone Marrow on Positron Emission Tomography/Computed Tomography for Prediction of Disease Progression in Cervical Cancer." International Journal of Gynecologic Cancer 27, no. 4 (May 2017): 776–83. http://dx.doi.org/10.1097/igc.0000000000000949.
Full textAbstract:
ObjectiveThis study aimed to evaluate the prognostic value of fluorine-18 fluorodeoxyglucose (FDG) uptake of bone marrow (BM) on positron emission tomography (PET)/computed tomography in patients with uterine cervical cancer.MethodsOne hundred forty-five patients with cervical cancer who underwent staging FDG PET/computed tomography and subsequent surgical resection or chemoradiotherapy were retrospectively enrolled in the study. Mean BM FDG uptake (BM standardized uptake value [SUV]) and BM-to-liver uptake ratio of FDG uptake (BLR) were measured. Relationships of BM SUV and BLR with hematologic and inflammatory markers were evaluated. Prognostic values of PET parameters for predicting disease progression-free survival and distant recurrence-free survival (DRFS) were assessed with a Cox proportional hazards regression model.ResultsBone marrow SUV and BLR were significantly correlated with white blood cell count and neutrophil-to-lymphocyte ratio. In the multivariate Cox regression analysis, International Federation of Gynecology and Obstetrics stage (P= 0.048), neutrophil-to-lymphocyte ratio (P= 0.028), platelet-to-lymphocyte ratio (PLR;P= 0.004), maximum SUV of cervical cancer (P= 0.030), and BLR (P= 0.031) were significantly associated with progression-free survival, whereas lymph node metastasis (P= 0.041), PLR (P= 0.002), and BLR (P= 0.025) were significantly associated with DRFS. In a patient subgroup with chemoradiotherapy, BLR (P= 0.044) was still an independent prognostic factor for predicting DRFS in multivariate analysis along with PLR (P= 0.004).ConclusionsIn patients with cervical cancer, BLR is associated with an increased risk of disease progression and distant recurrence.
9
Gray, David L., and Johan H. de Jong. "TUG USAGE FOR ESCORT AND RESCUE TOWING IN PRINCE WILLIAM SOUND, ALASKA." International Oil Spill Conference Proceedings 1995, no. 1 (February 1, 1995): 279–85. http://dx.doi.org/10.7901/2169-3358-1995-1-279.
Full textAbstract:
ABSTRACT The second part of the Prince William Sound Disabled Tanker Towing Study was undertaken to evaluate, using computer simulations, the capability of existing escort vessels in Prince William Sound, Alaska, and to examine alternatives that could enhance escort and rescue towing capabilities. The study was undertaken by The Glosten Associates, Inc., the Maritime Simulation Centre the Netherlands, and the Maritime Research Institute Netherlands on behalf of the Disabled Tanker Towing Study Group. A brief discussion of the project background, methodology, and results is contained herein.
10
Bronger, Holger, Philipp Hederich, Alexander Hapfelmeier, Stephan Metz, Peter B. Noël, Marion Kiechle, and Barbara Schmalfeldt. "Sarcopenia in Advanced Serous Ovarian Cancer." International Journal of Gynecologic Cancer 27, no. 2 (February 2017): 223–32. http://dx.doi.org/10.1097/igc.0000000000000867.
Full textAbstract:
ObjectiveCancer cachexia is a paraneoplastic syndrome comprising involuntary weight loss and muscle depletion (sarcopenia). Although weight loss has been associated with poor clinical outcome, there is only limited information on the prevalence and prognostic impact of sarcopenia in ovarian cancer so far.MethodsTotal skeletal muscle mass was determined by computed tomography image analysis of the third lumbar skeletal muscle cross-sectional area in 128 patients with advanced serous ovarian cancer. Longitudinal change of muscle mass was studied in 209 consecutive computed tomography scans from 43 patients. Association with survival was determined using Cox proportional hazards model.ResultsThe prevalence of sarcopenia at first diagnosis was 11% (12/105; 95% confidence interval [CI], 6%–20%). Sarcopenic patients had a significantly reduced progression-free (hazard ratio, 2.64; 95% CI, 1.24–5.64;P= 0.012) and overall survival (hazard ratio, 3.17; 95% CI, 1.29–7.80;P= 0.012). On multivariable analysis, these prognostic effects remained significant after adjustment for age, International Federation of Gynecology and Obstetrics stage, and postsurgical residual disease. Longitudinal analyses identified both patients with loss and gain of muscle mass. However, change in muscle mass over time was not associated with survival.ConclusionsBaseline sarcopenia is a prognostic factor in advanced serous ovarian cancer. Identification of sarcopenic patients and early enrollment in physical or nutritional education programs might thus be a feasible way to improve outcome and should be further evaluated in prospective clinical trials.
11
Usländer, Thomas, Felix Schöppenthau, Boris Schnebel, Sascha Heymann, Ljiljana Stojanovic, Kym Watson, Seungwook Nam, and Satoshi Morinaga. "Smart Factory Web—A Blueprint Architecture for Open Marketplaces for Industrial Production." Applied Sciences 11, no. 14 (July 17, 2021): 6585. http://dx.doi.org/10.3390/app11146585.
Full textAbstract:
The paper describes a reference architecture for open marketplaces to be used for networked stakeholders in industrial production ecosystems. The motivation for such an endeavor comes from the idea to apply the basic principle of the platform economy to offer functions of an asset “as a service” to industrial production, including the associated supply chain networks. Currently, commercial offers of “production as a service” usually lead to proprietary systems with the risk of platform vendor lock-ins. Hence, there is a need for an open approach that relies upon international (emerging) standards, especially those from IETF, IEC, the Plattform Industrie 4.0 and the International Data Spaces Association (IDSA). The presented approach enables federation of marketplaces according to well-defined interfaces. This article proposes a technology-independent open architecture derived from functional and non-functional system requirements and driven by the idea of the Smart Factory Web, a testbed of the Industrial Internet Consortium (IIC). Furthermore, the architecture of the Smart Factory Web (SFW) platform is presented and assessed against the current and future demands of open federated marketplaces for industrial production ecosystems.
12
Rogers, Martha. "Selective Exposure to Communication, Zillmann, Dolf and Jennings Bryant (Eds.). Hillsdale, New Jersey: Lawrence Erlbaum Associates, Inc., 1985. 251 Pp. $29.95." Journal of Advertising 16, no. 1 (March 1987): 69. http://dx.doi.org/10.1080/00913367.1987.10673065.
Full text
13
Gerard, Gregory J., and Severin V. Grabski. "International Lumberyards, Inc.: An Information System Consulting Case." Journal of Information Systems 16, no. 2 (September 1, 2002): 117–41. http://dx.doi.org/10.2308/jis.2002.16.2.117.
Full textAbstract:
Based on issues faced by an actual company, this case focuses on the design of an appropriate information systems architecture for International Lumberyards, Inc. (ILI). The design necessitates consideration of both the business strategy and the information technology that can support that strategy, since the business strategy needs to be both informed and supported by the information system. A strategy that is not supported by the requisite infrastructure will fail. Likewise, implementing technology that is not aligned with the business strategy will result, at a minimum, in a waste of resources. In the setting described in the case, the technology (or lack thereof) resulted in very constrained processes. A new technology infrastructure, aligned with the business strategy, will allow for future growth as well as addressing the limitations of the current environment. The case description forces consideration of how the organization's multiple locations will communicate with each other, and also what type of information systems software solution should be recommended. However, prior to the long-run goal of a new infrastructure, certain short-term solutions are needed to help the organization survive. The case includes teaching notes and has been designed for flexible classroom use. Due to the complexity of the case, it is recommended as an out-of-class project for use in graduate information systems classes. However, it could be used in undergraduate classes if the instructor provides additional guidance.
14
Amate, Pascale, Cyrille Huchon, Anne Lucie Dessapt, Chérazade Bensaid, Jacques Medioni, Marie-Aude Le Frère Belda, Anne-Sophie Bats, and Fabrice R. Lécuru. "Ovarian Cancer: Sites of Recurrence." International Journal of Gynecologic Cancer 23, no. 9 (November 2013): 1590–96. http://dx.doi.org/10.1097/igc.0000000000000007.
Full textAbstract:
IntroductionImproved knowledge of recurrence sites after contemporary surgical management of ovarian cancer is needed.Material and MethodsWe retrospectively reviewed consecutive patients managed for epithelial ovarian or tubal cancer with surgery and platinum-based chemotherapy between January 1, 2005, and December 31, 2009, in a tertiary teaching hospital. The site of first recurrence was recorded. Univariate analysis was performed to identify factors associated with site-specific recurrence. Overall survival and progression-free survival were computed using the Kaplan-Meier method, and log-rank tests were performed to assess the impact on survival of the variables of interest.ResultsRecurrences were noted in 3 (20%) of 15 International Federation of Gynecologists and Obstetricians stage I to IIa patients and 36 (62.1%) of 58 International Federation of Gynecologists and Obstetricians IIb to IV patients, and the median progression-free survival was 21.6 (2.5–71) and 19.3 (1.8–67.6) months, respectively. In the advanced-disease group, 75% of recurrences involved the peritoneum and 40% were confined to the peritoneum; peritoneal recurrences developed at both treated and untreated sites. Peritoneal recurrence was associated with greater initial peritoneal involvement (Sugarbaker score, 12.1 ± 8.2 vs 7.1 ± 7.4; P = 0.01) and residual postoperative tumor. Nodal recurrences were noted in 38% of all recurrences, usually in combination with peritoneal recurrence and in the abdominal territories. Isolated distant metastasis was a rare mode of recurrence (8%).ConclusionsThe peritoneum is the main recurrence site in both early and advanced ovarian cancer. Initial disease spread and extent of surgery are associated with the recurrence risk. This article supports the view that more attention should be directed toward extensive treatment of the peritoneum.
15
Capotosto, Thomas P. "Communications networks: A first course, by Jean Walrand, Irwin Inc. and Aksen Associates, Homewood, IL, 1991, 460 pp. Price: $52.95." Networks 24, no. 2 (March 1994): 126. http://dx.doi.org/10.1002/net.3230240215.
Full text
16
Bohr Mordhorst, Louise, Leif Karlsson, Berit Bärmark, and Bengt Sorbe. "Combined External and Intracavitary Irradiation in Treatment of Advanced Cervical Carcinomas: Predictive Factors for Treatment Outcome and Early and Late Radiation Reactions." International Journal of Gynecologic Cancer 24, no. 7 (September 2014): 1268–75. http://dx.doi.org/10.1097/igc.0000000000000208.
Full textAbstract:
ObjectiveThe objective of this study was to find out predictive factors of tumor control as well as acute and late radiation reactions in treatment of advanced cervical carcinomas.MethodsIn a series of 134 primary cervical carcinomas in International Federation of Gynecology and Obstetrics stages I to IV treated with combined external pelvic and intraluminal cervical-vaginal brachytherapy, predictive and prognostic factors were analyzed with regard to tumor control, recurrences, survival data, and adverse effects. Concomitant chemotherapy was given to 48 patients (35.8%). The external beam therapy was given with a 4-field technique (50–60 Gy) and brachytherapy was given with a high-dose rate (iridium-192) afterloading technique using a ring applicator set. A computed tomographically based 3-dimensional dose-planning system was used for the external beam therapy and for the brachytherapy planning. The mean age of the patients was 65 years. A total of 110 tumors were squamous cell carcinomas and 24 were adenocarcinomas or adenosquamous carcinomas. A total of 111 tumors were in International Federation of Gynecology and Obstetrics stages I to II; 23 tumors, in stages III to IV.ResultsThe primary control rate of the complete series was 92.5%. Tumor size, the brachytherapy dose, the combined external and brachytherapy dose, as well as the number of days of interruption (delay) of irradiation were all significant predictive factors for local tumor control. Forty recurrences (30%) were recorded. Early radiation reactions were recorded in 67% (mostly grade 1) and were associated with the widths of the anterior-posterior and lateral pelvic fields. Serious late radiations reactions (grade 3–4) were noted in 11%.ConclusionsThe width of the lateral pelvic fields, left point A and B doses, dose to the rectal reference point, as well as asymmetry of the dose distribution were associated with late severe reactions. Prior abdominal and pelvic surgery was also a high-risk factor for late tissue reactions. Concomitant chemotherapy did not increase the risk for acute or late toxicity.
17
Robinson, William, and Evelyn Cantillo. "Debulking Surgery and Intraperitoneal Chemotherapy Are Associated With Decreased Morbidity in Women Receiving Neoadjuvant Chemotherapy for Ovarian Cancer." International Journal of Gynecologic Cancer 24, no. 1 (January 2014): 43–47. http://dx.doi.org/10.1097/igc.0000000000000009.
Full textAbstract:
ObjectiveThe aims of this study were to compare the rate of completion of optimal debulking and/or 6 cycles of intraperitoneal (IP) chemotherapy in women with International Federation of Gynecologists and Obstetricians stage III/IV ovarian cancer undergoing neoadjuvant chemotherapy (NACT) versus primary surgery (PS) and to compare morbidity between these 2 groups.MethodsNinety-six subjects with stage III/IV ovarian cancer who underwent either NACT or PS were identified. Data comparisons include rate of optimal debulking and completion rate of 6 cycles of IP chemotherapy. Other data collected included surgical times, length of stay, intensive care unit admissions, blood transfusions, bowel resections, major complications, and dose reductions. SigmaStat version 2.0 was used for statistical analysis.ResultsOf the 96 subjects, 38 received NACT and 58 had PS. All 14 subjects with stage IV disease received NACT, and all experienced resolution of pleural effusion, based on computed tomographic imaging. Thirty-five (92%) of 38 NACT subjects versus 47 (81%) of 58 PS subjects were optimally debulked (P= 0.08). Thirty-six (95%) of 38 NACT subjects versus 37 (64%) of 58 PS subjects completed IP chemotherapy (P< 0.001). Length of stay was 3.26 (NACT) versus 5.08 (PS) days (P< 0.001). Intensive care unit admissions were 1 of 38 (NACT) versus 12 of 58 (PS) (P< 0.001). Bowel resections were done in 2 of 38 (NACT) versus 14 of 38 (PS) (P< 0.05). Duration of surgery was 96 minutes (NACT) versus 138 minutes (PS) (P< 0.001). A trend to fewer dose reductions occurred in NACT (1/38) versus PS (8/58) (P= 0.056).ConclusionsThe NACT subjects were more likely to complete IP chemotherapy and had decreased length of stay, intensive care unit admissions, bowel resections, and duration of surgery. Both optimal debulking and dose reductions were numerically but not statistically associated with NACT versus PS. This likely reflects a relatively high overall rate of optimal debulking and low rate of dose reductions in these subjects and would require a larger group to determine significance.
18
De Santis, Michele, Sandro Agnelli, Fabrizio Patanè, Oliviero Giannini, and Gino Bella. "Experimental Study for the Assessment of the Measurement Uncertainty Associated with Electric Powertrain Efficiency Using the Back-to-Back Direct Method." Energies 11, no. 12 (December 19, 2018): 3536. http://dx.doi.org/10.3390/en11123536.
Full textAbstract:
Brushless electric motors are used intensively in the industrial automation sector due to the motors low inertia and fast response. According to the International Electrotechnical Commission, IEC 60034-2-1, the efficiency of a three-phase electric machine (excluding machines for traction vehicles) can be determined by direct or indirect techniques. In the case of small traction motors (<10 kW), direct methods are used extensively by manufacturers, even if no standard has been published or scheduled by the IEC. In this paper, we evaluated the accuracy of the (direct) back-to-back method for the estimation of the energy performance of a 3 kW brushless AC electric motor used in a light electric vehicle. We measured the efficiencies of a pair of motors and inverters, as well as the overall efficiency of the entire power train. The results showed that the methodology was sufficiently accurate and comparable with other indirect methods available in existing literature. Moreover, we developed a Simulink model that used the powertrain efficiency map as the input to perform the simulation of a standard urban driving cycle. The simulation was run 500 times to calculate the probability density function associated with the total range of the vehicle, considering the uncertainty of the efficiency that was determined experimentally. The simulation results confirmed the low deviation of the distribution standard compared to the average value of the range of the vehicle.
19
Bartl, Thomas, Richard Schwameis, Anton Stift, Thomas Bachleitner-Hofmann, Alexander Reinthaller, Christoph Grimm, and Stephan Polterauer. "Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer." International Journal of Gynecologic Cancer 28, no. 9 (November 2018): 1664–71. http://dx.doi.org/10.1097/igc.0000000000001369.
Full textAbstract:
ObjectivesThe aims of this study were to assess anastomotic leakage (AL) rate and risk factors for AL in patients with advanced epithelial ovarian cancer (EOC) undergoing cytoreductive surgery including bowel resections and to evaluate the prognostic implication of AL.MethodsData of 350 consecutive patients with International Federation of Gynecology and Obstetrics EOC stage IIB–IV who underwent cytoreductive surgery at the Department of General Gynecology and Gynecologic Oncology of the General Hospital of Vienna between 2003 and 2017 were collected. Within this cohort, 192 patients (54.9%) underwent at least 1 bowel resection and were further analyzed. Preoperative risk factors for AL were computed using logistic regression models. Prognostic factors for overall survival were evaluated by using log-rank tests and multivariable Cox regression model.ResultsOverall, the AL rate was 4.7% for patients with advanced EOC undergoing cytoreductive surgery with at least 1 bowel resection, including patients with multiple large bowel resections. The AL rate for patients with isolated rectosigmoid resection was 1.9%. In univariate analysis, the number of anastomoses per surgery (P= 0.04) was associated with the occurrence of AL. In multivariable analysis, rectosigmoid resection with additional large bowel resection was associated with a higher risk of AL compared with isolated rectosigmoid resection (P= 0.046; odds ratio, 7.23 [95% confidence interval, 1.04–50.39]). Anastomotic leakage was associated with decreased overall survival (P= 0.04) in univariate but not in multivariable survival analysis.ConclusionsAnastomotic leakage rate after rectosigmoid resection in advanced EOC is acceptably low and outweighs increased perioperative risks when performed in a high-volume institution. Nonetheless, the occurrence of AL is a severe adverse event, which even seems to negatively affect patients’ overall prognosis. As no factor could be identified to clearly predict AL, extensive procedures comprising multiple bowel resections, should be avoided particularly when complete resection cannot be achieved.
20
King, Robert L. "Beville, Hugh Malcom, Jr. (1988), Audience Ratings: Radio, Television and Cable (Revised), Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., 407 Pp., $45.00 (cloth-bound); $19.95 (paperbound student Edition)." Journal of Advertising 18, no. 2 (June 1989): 47–48. http://dx.doi.org/10.1080/00913367.1989.10673154.
Full text
21
Xu, Dianbo, Danbo Wang, Shuo Wang, Ye Tian, Zaiqiu Long, and Xuemei Ren. "Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis." International Journal of Gynecologic Cancer 27, no. 9 (November 2017): 1935–42. http://dx.doi.org/10.1097/igc.0000000000001112.
Full textAbstract:
ObjectiveThe aim of this study was to analyze the relationship between serum squamous cell carcinoma antigen (SCC-Ag) and the clinicopathological features of cervical squamous cell carcinoma. The value of SCC-Ag and computed tomography (CT) for predicting lymph node metastasis (LNM) was evaluated.MethodsA total of 197 patients with International Federation of Gynecology and Obstetrics stages IB to IIA cervical squamous cell carcinoma who underwent radical surgery were enrolled in this study. The SCC-Ag was measured, and CT scans were used for the preoperative assessment of lymph node status.ResultsIncreased preoperative SCC-Ag levels were associated with International Federation of Gynecology and Obstetrics stage (P = 0.001), tumor diameter of greater than 4 cm (P < 0.001), lymphovascular invasion (P = 0.001), LNM (P < 0.001), and greater than one half stromal infiltration (P < 0.001). Multivariate analysis identified LNM (P < 0.001, odds ratio [OR] = 4.399), tumor diameter of greater than >4 cm (P = 0.001, OR = 4.019), and greater than one half stromal infiltration (P = 0.002, OR = 3.680) as independent factors affecting SCC-Ag greater than or equal to 2.35 ng/mL. In the analysis of LNM, SCC-Ag greater than or equal to 2.35 ng/mL (P < 0.001, OR = 4.825) was an independent factor for LNM. The area under the receiver operator characteristic curve (AUC) of SCC-Ag was 0.763 for all patients, and 0.805 and 0.530 for IB1 + IIA1 and IB2 + IIA2 patients, respectively; 2.35 ng/mL was the optimum cutoff for predicting LNM. The combination of CT and SCC-Ag showed a sensitivity and specificity of 82.9% and 66% in parallel tests, and 29.8% and 93.3% in serial tests, respectively.ConclusionsThe increase of SCC-Ag level in the preoperative phase means that there may be a pathological risk factor for postoperative outcomes. The SCC-Ag (≥2.35 ng/mL) may be a useful marker for predicting LNM of cervical cancer, especially in stages IB1 and IIA1, and the combination of SCC-Ag and CT may help identify patients with LNM to provide them with the most appropriate therapeutic approach.
22
Pransky, Joanne. "The Pransky interview: Charlie Duncheon, robotics serial entrepreneur, CEO and cofounder of Celltrio." Industrial Robot: the international journal of robotics research and application 48, no. 1 (February 26, 2021): 1–5. http://dx.doi.org/10.1108/ir-09-2020-0213.
Full textAbstract:
Purpose The purpose of this paper is to provide a “Q&A interview” conducted by Joanne Pransky of Industrial Robot Journal as a method to impart the combined technological, business and personal experience of a prominent, robotic industry engineer-turned entrepreneur regarding his pioneering efforts in the industrial robot industry and the commercialization and challenges of bringing robotic inventions to market. This paper aims to discuss these issues. Design/methodology/approach The interviewee is Charlie Duncheon, CEO, Cofounder and Chairman of the Board at Celltrio, Inc, a manufacturer of automation-based solutions for the life sciences industry. Duncheon shares his nearly 40-year journey as a robotics industry executive and entrepreneur, including his achievements and challenges. Findings Charlie Duncheon received a Bachelor of Science in industrial engineering from Purdue University and an MBA from Southern Illinois University, Edwardsville. At Monsanto, the first company he worked for after college, he worked his way up to be the Chairman of the Corporate Robotics Task Force. Duncheon then chose to work for the startup Fared Robot Systems, Inc., where he became the VP of Sales. In 1984, he joined Adept Technology at its inception and became Senior VP. About 20 years later, Duncheon founded his own consulting company, Duncheon Associates, and from the multiple consulting contracts he executed in automation, he was asked four different times to serve as the company CEO of the new companies: Artificial Muscle, Inc., EIG America, Grabit, Inc. and Celltrio, Inc., the last three which he also cofounded. Originality/value Charlie Duncheon, with a passion for robotic engineering and love for new challenges, led seven different robot companies to successful growth. His major accomplishments include establishing an unprecedented worldwide channel of 100+ integrators while at Adept Technology, growing Adept to $100m+ revenues and an initial public offering; being promoted to CEO of Artificial Muscle, Inc., later acquired by Bayer Material Science LLC; founding EIG America and transferring lithium battery technology from EIG Korea to the US market; and cofounding Grabit, Inc., raising two venture backed rounds of several million dollars. Duncheon is the recipient of the Joseph Engelberger Award for Leadership in Robotics. He is currently an Executive in Residence at Purdue University and a mentor for Plug and Play Tech Center. He was elected President of the Robotics Industries Association (RIA) and served a total of eight years on the RIA Board. He holds patents for automated material handling and electroadhesion grippers. His proudest accomplishment was the successful publication of his book, Reflections of a 5th Grade Girls Basketball Coach.
23
Abshier, Patricia. "Use of Virtual World for Soft/Communication Skills Training." International Journal of Gaming and Computer-Mediated Simulations 4, no. 3 (July 2012): 65–72. http://dx.doi.org/10.4018/jgcms.2012070105.
Full textAbstract:
The current state of the economy has created an increased pressure on companies to establish more efficient training programs, resulting in an upswing in e-learning and distance learning programs. With this increased demand for e-learning/distance learning training, the need for more interactive training that goes beyond the traditional webinar and video conference has also been identified. The literature regarding virtual learning platforms suggests that the use of simulations, both asynchronous and synchronous, holds great potential for enhancing the knowledge and skills of learning in a myriad of fields. Although these platforms are proving to have great benefits, they also are showing some challenges and barriers to overcome. After a review of current research, Cicatelli Associates, Inc. (CAI), conducted an internal feasibility study to determine the feasibility of the use of virtual worlds in training healthcare and health care service provision staff in general counseling skills and communications skills. After examining, both the strengths and the challenges of utilizing this method for training it was determined that several barriers exist that currently prohibit the organization from using this method. These barriers include access to appropriate computer systems, as well as the lack of fine or micro non-verbal gestures in virtual worlds.
24
Amornvit, Pokpong, and Sasiwimol Sanohkan. "The Accuracy of Digital Face Scans Obtained from 3D Scanners: An In Vitro Study." International Journal of Environmental Research and Public Health 16, no. 24 (December 12, 2019): 5061. http://dx.doi.org/10.3390/ijerph16245061.
Full textAbstract:
Face scanners promise wide applications in medicine and dentistry, including facial recognition, capturing facial emotions, facial cosmetic planning and surgery, and maxillofacial rehabilitation. Higher accuracy improves the quality of the data recorded from the face scanner, which ultimately, will improve the outcome. Although there are various face scanners available on the market, there is no evidence of a suitable face scanner for practical applications. The aim of this in vitro study was to analyze the face scans obtained from four scanners; EinScan Pro (EP), EinScan Pro 2X Plus (EP+) (Shining 3D Tech. Co., Ltd. Hangzhou, China), iPhone X (IPX) (Apple Store, Cupertino, CA, USA), and Planmeca ProMax 3D Mid (PM) (Planmeca USA, Inc. IL, USA), and to compare scans obtained from various scanners with the control (measured from Vernier caliper). This should help to identify the appropriate scanner for face scanning. A master face model was created and printed from polylactic acid using the resolution of 200 microns on x, y, and z axes and designed in Rhinoceros 3D modeling software (Rhino, Robert McNeel and Associates for Windows, Washington DC, USA). The face models were 3D scanned with four scanners, five times, according to the manufacturer’s recommendations; EinScan Pro (Shining 3D Tech. Co., Ltd. Hangzhou, China), EinScan Pro 2X Plus (Shining 3D Tech. Co., Ltd. Hangzhou, China) using Shining Software, iPhone X (Apple Store, Cupertino, CA, USA) using Bellus3D Face Application (Bellus3D, version 1.6.2, Bellus3D, Inc. Campbell, CA, USA), and Planmeca ProMax 3D Mid (PM) (Planmeca USA, Inc. IL, USA). Scan data files were saved as stereolithography (STL) files for the measurements. From the STL files, digital face models are created in the computer using Rhinoceros 3D modeling software (Rhino, Robert McNeel and Associates for Windows, Washington DC, USA). Various measurements were measured five times from the reference points in three axes (x, y, and z) using a digital Vernier caliper (VC) (Mitutoyo 150 mm Digital Caliper, Mitutoyo Co., Kanagawa, Japan), and the mean was calculated, which was used as the control. Measurements were measured on the digital face models of EP, EP+, IPX, and PM using Rhinoceros 3D modeling software (Rhino, Robert McNeel and Associates for Windows, Washington DC, USA). The descriptive statistics were done from SPSS version 20 (IBM Company, Chicago, USA). One-way ANOVA with post hoc using Scheffe was done to analyze the differences between the control and the scans (EP, EP+, IPX, and PM). The significance level was set at p = 0.05. EP+ showed the highest accuracy. EP showed medium accuracy and some lesser accuracy (accurate until 10 mm of length), but IPX and PM showed the least accuracy. EP+ showed accuracy in measuring the 2 mm of depth (diameter 6 mm). All other scanners (EP, IPX, and PM) showed less accuracy in measuring depth. Finally, the accuracy of an optical scan is dependent on the technology used by each scanner. It is recommended to use EP+ for face scanning.
25
Brock, John F. "Applying ISD to a Social Problem: Systematic Development of a Driver Training Computer-Based Program." Proceedings of the Human Factors and Ergonomics Society Annual Meeting 42, no. 20 (October 1998): 1393. http://dx.doi.org/10.1177/154193129804202006.
Full textAbstract:
Traditionally, Instructional Systems Development (ISD) has been applied on large, primarily military training systems. Many skill-based training programs in the civilian world have followed the more traditional textbook, lecture, written-test model of the public educational system. In the meantime, after 70 years of public and private higher education over 6,000 young persons a year are killed in traffic crashes. It is well established that exposure to driver education does not correlate with either fewer crashes, or fewer traffic violations. This symposium reports on a three-year program that applied ISD techniques to the development of CD-ROM program for young drivers. The first paper, by Dr. David Willis of the AAA Foundation for Traffic Safety, reports on the early needs analysis which identified a new approach to driving instruction as a potential intervention for young drivers. The second paper, by Larry Lonero of Northport Associates, describes the curriculum development effort which identified, among many, a set of specific learning objectives which were used to design the CD-ROM program described and demonstrated in the third paper, presented by Dr. Deborah Blank of Electronic Learning Facilitators, Inc. Finally, the fourth paper, by Dr. Donald Fisher of the University of Massachusetts, reports on the test and evaluation of the CD-ROM program using an advanced driving simulator.
26
Togami, Shinichi, Toshihiko Kawamura, Shintaro Yanazume, Masaki Kamio, and Hiroaki Kobayashi. "Comparison of lymphoscintigraphy and single photon emission computed tomography with computed tomography (SPECT/CT) for sentinel lymph node detection in endometrial cancer." International Journal of Gynecologic Cancer 30, no. 5 (March 21, 2020): 626–30. http://dx.doi.org/10.1136/ijgc-2019-001154.
Full textAbstract:
BackgroundEndometrial cancer is the most common gynecologic cancer, and lymph node metastasis is one of the most important prognostic factors. Increasing evidence shows that sentinel lymph node (SLN) mapping is an effective alternative to comprehensive lymphadenectomy. Single photon emission CT with computed tomography (SPECT/CT) is associated with a high SLN detection rate.ObjectiveTo compare the clinical efficacy of SPECT/CT with that of lymphoscintigraphy in detecting SLNs in patients with endometrial cancer.MethodsBetween May 2014 and October 2018, 151 patients with endometrial cancer were enrolled in this study at the Department of Obstetrics and Gynecology of the Kagoshima University Hospital. Inclusion criteria were patients with endometrial cancer, older than 18 years, and with pre-operative International Federation of Gynecology and Obstetrics (FIGO) staging of I and II. All patients underwent pre-operative CT, and patients with suspected peritoneal dissemination and lymph node metastasis were excluded from this study. Pelvic SLNs were detected by injection of tecnetium-99m-labeled phytate into the uterine cervix. The number and locations of SLNs detected using lymphoscintigraphy and SPECT/CT were evaluated. JMP software (version 14, SAS Institute Inc., Cary, North Carolina, USA) was used for statistical analysis.ResultsA total of 151 patients who underwent pre-operative lymphoscintigraphy and SPECT/CT were included in the study. The median age was 57 years (range 24–79), and the median body mass index was 24.3 kg/m2 (range 16–40). The final pathology was as follows: 135 (89%) endometrioid carcinoma, 11 (7%) serous carcinoma, one (1%) clear cell carcinoma, and four (3%) other histotypes. Based on SPECT/CT, 204 pelvic SLNs were detected. The bilateral pelvic SLN detection rate was better for SPECT/CT (43% (65/151)) than for lymphoscintigraphy (32% (48/151)) (p<0.0001). The overall pelvic SLN detection rate (at least one pelvic SLN detected) was also better with SPECT/CT (77% (16/151)) vs lymphoscintigraphy (68% (102/151)) (p<0.0001). The distribution of SLN locations detected using SPECT/CT was as follows: external iliac, 91 (45%); obturator, 61 (30%); common iliac, 28 (14%); internal iliac, 19 (9%); para-aortic, 2 (1%); parametrium, 2 (1%), and presacral, 1 (1%). The SLN detection rate using SPECT/CT was significantly worse in patients of advanced age (p<0.0001).DiscussionOverall and bilateral SLN detection rate was better with SPECT/CT than with lymphoscintigraphy in patients with stage I/II endometrial cancer.
27
McCovern, Christine. "BRAIN INJURY AND NEUROPSYCHOLOGICAL REHABILITATION: INTERNATIONAL PERSPECTIVES. 1994. 1st Edition. Edited by Anne-Lise Christensen and Barbara P. Uzzell. Published by Lawrence Erlbaum Associates, Inc. 341 pages. $C47.00." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 22, no. 4 (November 1995): 337. http://dx.doi.org/10.1017/s0317167100039676.
Full text
28
Chen, Chyong Ling Judy, and Susan Margaret Belcher. "The Importance of Absorptive Capacity in the Road to Becoming a “Giant Lion”—ASUSTek Computer Inc." Global Economic Review 39, no. 3 (September 2010): 291–315. http://dx.doi.org/10.1080/1226508x.2010.513142.
Full text
29
Strauch, A. Bruce. "Copyright protection for the artfully sweaty: Feist Publications, Inc. v. Rural Telephone Service Co., Inc." Publishing Research Quarterly 10, no. 1 (March 1994): 66–72. http://dx.doi.org/10.1007/bf02680438.
Full text
30
Tucker, K. "Brain injury and neuropsychological rehabilitation: International perspectives Edited by A. L. Christensen & B. P. Uzzell. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., 1994. 341 pp., $36.00 paperback, $69.95 hardcover." Archives of Clinical Neuropsychology 11, no. 6 (1996): 553–55. http://dx.doi.org/10.1016/0887-6177(95)00030-5.
Full text
31
Jaiswal, Mayank, and Robert Maxwell. "The trials and tribulations of JTH Inc." CASE Journal 15, no. 2 (March 30, 2019): 88–108. http://dx.doi.org/10.1108/tcj-06-2018-0065.
Full textAbstract:
Theoretical basis The theoretical linkages are with dynamic nature of PESTEL analysis, Porter’s five forces, resource-based view of the firm and characteristics of an entrepreneur. Research methodology The names of the institutions and individuals involved have been disguised. However, the material facts of the case are authentic. Case overview/synopsis This case discusses strategy in the context of a crisis situation in a small business. JTH Inc. was a computer subcontract manufacturing (SCM) firm serving the New England region of the USA. The influx of international competition (mainly from China) due to recession led to significant challenges for JTH and the SCM industry. JTH was struggling and the situation was further complicated by the founder’s (Robert Maxwell) personal and emotional situation. Robert had to decide whether to keep the business running, close it down, merge with/be acquired by a competitor, innovate the business model or do something else. Complexity academic level This case is designed to target undergraduate students of Strategic Management; it may also include Entrepreneurship students. It should most probably be taught in the first half of the course after concepts such as PESTEL, Porter and resource-based view of the firm have been taught.
32
Albano, Mariana, Melissa J. Karau, Audrey N. Schuetz, and Robin Patel. "Comparison of Agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli." Journal of Clinical Microbiology 59, no. 1 (September 23, 2020): e00966-20. http://dx.doi.org/10.1128/jcm.00966-20.
Full textAbstract:
ABSTRACTCefiderocol (CFDC) is a siderophore cephalosporin with activity against Gram-negative bacterial species that are resistant to carbapenems and other drugs. The MICs of CFDC were determined for 610 Gram-negative bacilli, including 302 multinational Enterobacterales isolates with characterized mechanisms of beta-lactam resistance, 180 clinical isolates from the Mayo Clinic and Mayo Clinic Laboratories not characterized for specific resistance mechanisms, and 128 isolates with CFDC MICs of ≥8 μg/ml obtained from International Health Management Associates, Inc. (IHMA, Schaumburg, IL). Broth microdilution using standard cation-adjusted Mueller-Hinton broth (BMD) and iron-depleted cation-adjusted Mueller-Hinton broth (ID-BMD), and agar dilution (AD) using standard Mueller-Hinton agar were performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines. MICs were interpreted according to the investigational CLSI, FDA, and EUCAST breakpoints, and results were compared. MICs inhibiting 50 and 90% of organisms (MIC50 and MIC90, respectively), essential agreement (EA), categorical agreement (CA), and error of different types were determined. Results showed considerable discordance between AD and ID-BMD. CFDC showed low EA and CA rates and high error rates for AD in comparison to ID-BMD. Overall, this study does not support use of standard AD for determining CFDC MICs.
33
Lu, Nan-You, Patrick Hawbecker, Sukanta Basu, and Lance Manuel. "On Wind Turbine Loads During Thunderstorm Downbursts in Contrasting Atmospheric Stability Regimes." Energies 12, no. 14 (July 19, 2019): 2773. http://dx.doi.org/10.3390/en12142773.
Full textAbstract:
Severe winds produced by thunderstorm downbursts pose a serious risk to the structural integrity of wind turbines. However, guidelines for wind turbine design (such as the International Electrotechnical Commission Standard, IEC 61400-1) do not describe the key physical characteristics of such events realistically. In this study, a large-eddy simulation model is employed to generate several idealized downburst events during contrasting atmospheric stability conditions that range from convective through neutral to stable. Wind and turbulence fields generated from this dataset are then used as inflow for a 5-MW land-based wind turbine model; associated turbine loads are estimated and compared for the different inflow conditions. We first discuss time-varying characteristics of the turbine-scale flow fields during the downbursts; next, we investigate the relationship between the velocity time series and turbine loads as well as the influence and effectiveness of turbine control systems (for blade pitch and nacelle yaw). Finally, a statistical analysis is conducted to assess the distinct influences of the contrasting stability regimes on extreme and fatigue loads on the wind turbine.
34
Kaufmann, William. "Annual Reviews inc. A saga of success." Publishing Research Quarterly 11, no. 2 (June 1995): 80–89. http://dx.doi.org/10.1007/bf02680428.
Full text
35
Míguez, José, Jacobo Porteiro, Raquel Pérez-Orozco, and Miguel Gómez. "Technology Evolution in Membrane-Based CCS." Energies 11, no. 11 (November 14, 2018): 3153. http://dx.doi.org/10.3390/en11113153.
Full textAbstract:
In recent years, many CO2 capture technologies have been developed due to growing awareness about the importance of reducing greenhouse gas emissions. In this paper, publications from the last decade addressing this topic were analyzed, paying special attention to patent status to provide useful information for policymakers, industry, and businesses and to help determine the direction of future research. To show the most current patent activity related to carbon capture using membrane technology, we collected 2749 patent documents and 572 scientific papers. The results demonstrated that membranes are a developing field, with the number of applications growing at a steady pace, exceeding 100 applications per year in 2013 and 2014. North American assignees were the main contributors, with the greatest number of patents owned by companies such as UOP LLC, Kilimanjaro Energy Inc., and Membrane Technology and Research Inc., making up 26% of the total number of published patents. Asian countries (China, Japan, and Korea) and international offices were also important knowledge sources, providing 29% and 24% of the documents, respectively. Furthermore, this paper highlights 10 more valuable patents regarding their degree of innovation and citations, classified as Y02C 10/10 according to the Cooperative Patent Classification (CPC) criteria.
36
Olson, Jeff, Jeff Pan, Jill Hochlowski, Philip Searle, and Dave Blanchard. "Customization of a Commercially Available Prep Scale SFC System to Provide Enhanced Capabilities." JALA: Journal of the Association for Laboratory Automation 7, no. 4 (August 2002): 69–74. http://dx.doi.org/10.1016/s1535-5535-04-00210-2.
Full textAbstract:
Preparative Scale Supercritical Fluid Chromatography is emerging as a powerful alternative to HPLC for the purification and separation of complex chemical reaction mixtures. Advantages include greatly reduced solvent usage (and thus lower cost and environmental impact), higher throughput, and in some cases higher resolution. While there are commercially available prep SFC instruments, none currently offer all the features desired by many medicinal chemists engaged in the drug discovery process. These include: the ability to collect an unlimited number of fractions per sample with high recovery and negligible carryover, fully automated capacity to collect several hundred fractions, and the ability to collect fractions into the same disposable test tubes and racks which are already employed in HPLC. This article describes the customization of a preparatory scale SFC system purchased from Berger Instruments, Inc., Newark, DE. (a subsidiary Mettler-Toledo International, Inc., of Greifensee, Switzerland) in order to provide these capabilities.
37
Goy, Andre, Tommy Wu, Eric Hansen, Srikesh Arunajadai, Ewelina Protomastro, Marisa Valentinetti, Maureen Murphy, et al. "Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma (MCL)." Blood 128, no. 22 (December 2, 2016): 2973. http://dx.doi.org/10.1182/blood.v128.22.2973.2973.
Full textAbstract:
Abstract Introduction: The outcome of MCL patients (pts) has improved over the last three decades, although this is debated outside clinical trials (Chandran, Leuk Lymphoma Aug 2012; Smith, Br J Cancer. April 2015). The Mantle Cell International Prognostic Index (MIPI) (Hoster, Blood Jan 2008) is based on 4 variables which predict survival: age (host factor), PS (tumor/host), LDH (tumor burden) and WBC (leukemic phase). The additional value of including co-morbidities into risk stratification has not been fully explored. Methods: Using the COTA database we retrospectively analyzed MCL cases treated at John Theurer Cancer Center and the affiliated practices of Regional Cancer Care Associates from 2004 to 2016. Clinical and treatment characteristics, including calculation of the CCI index (Charlson J Chronic Diseases 1987) were captured via the COTA platform by extracting data from the electronic health records. Results: 490 pts with MCL were evaluated and full longitudinal data from diagnosis is currently reported on 195 subjects. Pts characteristics included: male (66.15%), med age (65, range 34-94), stage IV (87%), LDH (elevated 26%; median 197, range 112-7950), MIPI (low 38%, interm 32%, high 30%), Ki-67 (≥30%: 51%, 86 NA), blastoid variant (16%, 35 NA), SOX-11 positive (87%, 143 NA), 17p abnormalities (p53 del or overexpression/mutation (24%, 88 NA) and b-2 microglobulin (b-2m) > 3 mg/L (52%). Frontline therapy consisted of R-Hyper-CVAD (with or without bortezomib on study) (36%), R-HyperCVAD or R-CHOP followed by high-dose therapy followed by autologous stem cell transplantation (ASCT) (9%), BR alone (8%), BR+ maintenance (8%), R-CHOP alone (4%), Rituximab (3%), R-BAC (3%), BR+ Ibrutinib vs placebo (2%), radiation (2%), R-Lenalidomide (1%), R-CHOP + maintenance (1%), other treatments (10%) while 10% of patients were treated expectantly Seventeen pts underwent ASCT consolidation (15 auto vs 2 allo (del17p/blastoid at presentation). Overall and progression free survival was computed using Kaplan Meier curves and significance tested using log-rank tests. The 5y OS for this entire cohort was 81. Overall, dose-intensive strategies (with or without ASCT) approach was associated with a 23 mo difference in PFS (median 74 mo, range 0-111 mo (intensive) vs median 51 mo, range 2-57 mo for the non-intensive group (p=0.37). The median OS was not reached for either group, with a 5y OS of 88% in intensive vs. 71% non-intensive regimens (p=0.14). Using MIPI as stratification, low/intermediate risk pts had similar outcome in intensive and non-intensive therapy groups (5y OS 88% vs 71%; p=0.13). Pts with high MIPI had a 5 year OS of 80% in the intensive therapy group vs 46% for non-intensive group (p=0.376). The CCI scores for the whole cohort were 0 in 16 pts (8%), 1-3 in 81 pts (41%), and ≥ 4 in 98 pts (50%). Baseline CCI score (pre-treatment) was highly predictive of outcome with a 5y OS of 90% in CCI 0-3 vs 62% in CCI 3+ (p=0.001) (Figure 1). CCI did not predict complete response rate (CR) to induction therapy (CCI 0-3 94% vs CCI 3+ 80%). The median MIPI scores were 5.7 for CCI 0-3 and 6.3 for CCI 3+. Age is a component of both indexes but more heavily weighted in the CCI. Adding CCI to MIPI defined a subset of pts among the high MIPI group who did better than expected with a 5y OS of 88% in combined high MIPI / CCI 0-3 vs 31% for high MIPI / CCI 4+/ (p=0.03). b-2m (cut-off 3mg/L) correlated with 5y OS 93% vs 80%; (p=0.04) as previously reported but did not add to MIPI or CCI risk stratification. Ki-67 (30% cut-off) was marginally associated with OS: 5-y 89% vs 77% (p=0.06). Conclusions: Our cohort is consistent with the improvement of MCL outcome comparing to historical controls and illustrates the importance of comorbidities captured at baseline. A combined CCI-MIPI approach might help identify pts who can still benefit from current therapy approaches in spite of age. Among the high MIPI score group, CCI further refines cohorts with significantly different outcomes. Figure 1 Figure 1. FIgure 2 FIgure 2. Disclosures Goy: Acerta: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Other: Research funding for clinical trials through institution; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; COTA: Membership on an entity's Board of Directors or advisory committees; Janssen/Pharmacyclics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Research funding for clinical trials through institution, Speakers Bureau; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Research funding for clinical trials through institution. Wu:COTA: Employment. Hansen:COTA: Employment. Arunajadai:COTA: Employment. Protomastro:COTA: Employment. Valentinetti:COTA: Employment. Murphy:COTA: Employment. Smith:COTA: Employment. Pe Benito:COTA: Employment. Hasan:COTA: Employment. Suryadevara:COTA: Employment. Feldman:Seattle Genetics: Consultancy, Speakers Bureau; Abbvie: Consultancy, Speakers Bureau; Pharmacyclics: Speakers Bureau; Celgene: Speakers Bureau. Skarbnik:Pharmacyclics: Consultancy; Genentech: Speakers Bureau; Seattle Genetics: Speakers Bureau; Gilead Sciences: Speakers Bureau; Abbvie: Consultancy. Leslie:Celgene: Speakers Bureau; Seattle Genetics: Speakers Bureau. Pecora:COTA: Employment, Equity Ownership. Goldberg:Bristol Myers Squibb, Novartis: Speakers Bureau; Neostem: Equity Ownership; Novartis: Consultancy; COTA Inc: Employment; Pfizer: Honoraria.
38
Choi, William W., Barth A. Green, and Allan D. O. Levi. "Computer-assisted Fluoroscopic Targeting System for Pedicle Screw Insertion." Neurosurgery 47, no. 4 (October 1, 2000): 872–78. http://dx.doi.org/10.1097/00006123-200010000-00017.
Full textAbstract:
Abstract OBJECTIVE Biplanar fluoroscopic imaging linked to a computer-driven mechanical end-effector is under development as a targeting system for spinal surgery. This technology has the potential to enhance standard intraoperative fluoroscopic information for localization of the pedicle entry point and trajectory, and it may be an effective alternative to the computed tomography-based image-guided system (IGS) in pedicle screw placement. A preclinical study to assess the accuracy and time efficiency of this system versus a conventional IGS was conducted. METHODS Pedicle screw placement was performed in six cadavers from T1 to S1 levels using the ViewPoint IGS (Picker International, Inc., Cleveland, OH) on one side versus the Fluorotactic guidance system (Z-Kat, Inc., Miami, FL) on the other side. Of 216 possible pedicles, 208 were instrumented; 8 pedicle diameters were too small or were not adequately imaged. Postinsertion, each pedicle was assessed for the presence and location of cortical perforation using computed tomographic scanning and direct visualization. RESULTS The number of successful screw placements was 89 (87.3%) of 102 for IGS and 87 (82.1%) of 106 for the Fluorotactic guidance system, respectively. The mean time to register and operate on one level using the Fluorotactic guidance system was 14:34 minutes (minutes:seconds), compared with 6:50 minutes using the IGS. The average fluoroscope time was 4.6 seconds per pedicle. CONCLUSION Our data indicate that this first-generation fluoroscopy-based targeting system can significantly assist the surgeon in pedicle screw placement. The overall accuracy is comparable to an IGS, especially in the region of T9–L5. A second-generation system with a faster end-effector and user-friendly interface should significantly reduce the operating and fluoroscope time.
39
Kortum, Philip T., and S. Camille Peres. "Posters With Fellows." Proceedings of the Human Factors and Ergonomics Society Annual Meeting 60, no. 1 (September 2016): 1838. http://dx.doi.org/10.1177/1541931213601419.
Full textAbstract:
Posters With Fellows is an opportunity to interact with some of the best scholars the Human Factors and Ergonomics Society has to offer in a low-key, intellectual setting. Fellows will present posters describing cutting-edge research from their current work, retrospectives of important work they have conducted over their careers, and descriptions of challenging new frontiers they think need to be addressed. This is a unique opportunity for students and professionals alike to talk one on one with the thought leaders of our profession on the important research issues of our time. Participants: Thomas J. Armstrong, University of Michigan, Ann Arbor Deborah A. Boehm-Davis, George Mason University Gloria L. Calhoun, U.S. Air Force Stanley H. Caplan, Usability Associates Nancy J. Cooke, Arizona State University Kermit G. Davis, University of Cincinnati Valerie J. Gawron, MITRE Corp. Douglas J. Gillan, North Carolina State University Wayne D. Gray, Rensselaer Polytechnic Institute Joel S. Greenstein, Clemson University M. Susan Hallbeck, Mayo Clinic Peter A. Hancock, University of Central Florida Robert Hoffman, Institute for Human & Machine Cognition Edmond W. Israelski, Abbvie Brian M. Kleiner, Virginia Tech Arnold M. Lund, Amazon Lab126 Thomas B. Malone, Carlow International Inc. Kathleen L. Mosier, San Francisco State University Robert W. Proctor, Purdue University Ronald G. Shapiro Matthew B. Weinger, Vanderbilt University Christopher D. Wickens, Alion Science & Technology
40
Ryan, Fiona, Stephen Byrne, and Susan O’Shea. "Randomized Controlled Trial of Supervised Patient Self-Testing of Warfarin Therapy Using An Internet Based Expert System." Blood 112, no. 11 (November 16, 2008): 879. http://dx.doi.org/10.1182/blood.v112.11.879.879.
Full textAbstract:
Abstract Improved anticoagulation control results in improved outcomes, with a decrease in the incidence of bleeding and thromboembolic events. The outcomes of oral anticoagulation therapy (OAT) are dependent on the model of care used to manage warfarin therapy, with better outcomes associated with the use of a specialised anticoagulation management service (AMS), computerized decision support and increased testing frequency (facilitated by patient self-testing (PST) of the international normalised ratio (INR)) (Ansell and Hughes 1996). This study uses a novel strategy to combine the advantages of these three approaches to warfarin management. A prospective, randomized controlled cross-over study was carried out at the anticoagulation clinic of Cork University Hospital, Ireland, to test the hypothesis that supervised PST using an internet based expert system could provide comparable anticoagulation control to that provided by traditional outpatient AMS management. This was a cross-over study; patients served in both AMS and supervised PST arms, with random assignment as to the order of management. Both arms were six months in duration. Patients on established long term OAT who had internet access were eligible for enrolment. During the supervised PST arm of the study, patients measured their INR at home using the CoaguChek XS® point of care meter, (Roche Diagnostics, UK) either twice weekly, weekly or every two weeks depending on their anticoagulation control. They entered this result along with other information relating to their warfarin therapy (e.g. signs or symptoms of thrombosis or hemorrhage, missed doses, concurrent illnesses, dietary or medication changes etc) onto the CoagCare® (Zycare Inc, Chapel Hill, NC) web page. Patients with a therapeutic INR and no other issues were automatically provided with algorithm-derived dosing and repeat testing instructions. Patients with non-therapeutic results, or symptoms suggestive of thromboembolic or hemorrhagic complications, were prioritized for caregiver review according to problem severity. During the AMS arm, patients were required to attend the clinic every four to six weeks, or more frequently, if clinically indicated. Dosage adjustments were performed by the anticoagulant clinic staff using the laboratory INR and the APEX® (iSOFT, UK) computer decision support software. The primary outcome variable to assess anticoagulation control was the difference in time in therapeutic range (TTR) during the AMS management and supervised PST management period. In addition, the number of INR measurements indicative of serious under- or over-anticoagulation and the number of serious hemorrhagic or thrombotic adverse events were also compared. One hundred and sixty two patients were enrolled over a nine-month period (July 2006–April 2007). The majority of study patients were male (61.4%) and the mean age of the study population was 59.6 +/−14.3 years. One hundred and thirty two (81.5%) patients completed both arms of the study. The mean TTR during the AMS arm was 60.2% +/−19.5%, which increased to 71.4% +/− 13.6% during the PST period (p<0.001). Eighty-seven patients (65.91%) achieved better anticoagulation control during the supervised PST period. Patients measured their INR almost four times more frequently while home-testing giving a mean frequency of INR testing of 4.5 days compared with 17.4 days for the AMS period. Extreme INR values (< 1.5 and > 5.0) occurred more frequently during the AMS arm of the study (6% vs 2.4%, p<0.001). There was no significant difference in the adverse event rate between the two study periods. Table 1. Table 1. Adverse events Model of care Hemorrhagic Thromboembolic AMS Gastric bleed (INR 2.5) TIA (INR 2.2) Supervised PST None DVT (INR 1.6) DVT (1.4) Daily time to manage 70 patients ranged from 10 to 45 minutes (mean 23.19+/−9.48 mins/day). This novel system of supervised PST using an internet based expert system improves the clinical effectiveness of OAT when compared with management by a specialized anticoagulant management service.
41
Austin, Barbara. "Developing Superior Work Teams: Building Quality and the Competitive EdgeDeveloping Superior Work Teams: Building Quality and the Competitive Edge By KinlawDennis C., San Diego: Lexington Books/University Associates, Inc., 1991—199 Pages. $29.95." Academy of Management Perspectives 6, no. 1 (February 1992): 97–98. http://dx.doi.org/10.5465/ame.1992.4274383.
Full text
42
Martin, N. G. "Proceedings of the Second International Conference on Quantitative Genetics, edited by B.S. Weir, E.J. Eisen, M.M. Goodman, and G. Namkoong, Sunderland, MA: Sinauer Associates Inc., 1988, xii + 724 pages, $60.00 (cloth), $38.50 (paper)." Genetic Epidemiology 6, no. 2 (1989): 389–90. http://dx.doi.org/10.1002/gepi.1370060208.
Full text
43
Hornberger, John, Minghan Dai, Hans-Peter Goertz, Keith L. Dawson, and Carolina Reyes. "Does Faster Rituximab Infusion for Patients with NHL Lower Cancer Care Costs?" Blood 120, no. 21 (November 16, 2012): 2063. http://dx.doi.org/10.1182/blood.v120.21.2063.2063.
Full textAbstract:
Abstract Abstract 2063 Introduction Rituximab in combination with chemotherapy is a recommended regimen for non-Hodgkin's lymphoma (NHL), which has been shown in randomized trials and real-world studies to provide a survival benefit compared with chemotherapy alone. Per the US Prescribing Information (USPI), rituximab is typically administered over 4–6 hours for the first infusion and 3–4 hours for subsequent infusions. A 90-minute infusion schedule for rituximab has been found to be safe and feasible in NHL patients who tolerate their first infusion administered at the standard rate and who do not have significant cardiovascular disease or high circulating lymphocytes. This study's primary objective was to assess the cost from a US societal perspective of faster 90-minute rituximab infusion vs the conventional 4–6 hour rituximab infusion. Methods Analyses were performed in accordance with best research guidelines of the International Society of Pharmacoeconomic Outcomes and Research. The target population was patients with previously untreated diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who were scheduled to receive rituximab 375 mg/m2plus CHOP or CVP chemotherapy. Medical resources assessed were: chemotherapy administration, chemotherapy and pre-treatment drugs, and Grade 3/4 adverse events. Indirect costs include societal resources such as income foregone by patients and informal caregivers/spouses as a result of visit duration for infusion. Trial data were used to extract event rates of adverse events and duration of infusions, and patient drop-out rate by cycle. Prices for medical resources were obtained from publicly available Medicare Fee Schedules. Per capita hourly wage rates were extracted from statistics of the US Labor Department. Outcomes were costs per year for patients treated in the US and cost per infusion and per course of therapy in 2012 US dollars. Results A projected 23,519 newly diagnosed DLBCL and FL patients comprise the target population. Estimated total direct medical cost for conventional infusion is $925,318,162 and $9,855,416 in foregone income for patients and caregivers. The 90-minute infusion reduced direct medical costs by $22,362,397 (2%) and foregone income for patients and caregivers by $5,115,629 (52%). The average cost savings were $359 per infusion and $2,119 per course. The most influential parameters were administration cost and patient foregone income due to time for infusions. The savings per course may be greater if infusion centers are able to spread fixed costs, e.g., overhead, among a greater number of patients resulting from increased capacity to schedule more patients. Conclusion The 90-minute rituximab infusion has been found to be a safe and feasible alternative to conventional rituximab infusion for patients with untreated DBLCL or FL. In an era of landmark legislation (The Patient Protection and Affordable Care Act of 2010) designed to address concerns about rising costs of healthcare and place more emphasis on patient-centered research, the faster rituximab infusion regimen offers direct medical savings and reduces foregone income to patients and caregivers. Disclosures: Hornberger: Cedar Associates LLC: Employment; Genentech, A Member of the Roche Group: Research Funding. Off Label Use: Rituxan (Rituximab) - faster infusion is off-label. Dai:Cedar Associates: Employment; Genentech, Inc, A Member of the Roche Group: Research Funding. Goertz:Genentech, Inc, A Member of the Roche Group: Employment, Equity Ownership. Dawson:Genentech, A Member of the Roche Group: Employment, Equity Ownership. Reyes:Genentech, Inc, A Member of the Roche Group: Employment, Equity Ownership.
44
Thornton, Jack. "Penetrating New Ground." Mechanical Engineering 121, no. 05 (May 1, 1999): 70–71. http://dx.doi.org/10.1115/1.1999-may-6.
Full textAbstract:
Sensors & Software Inc. (S&S) is adapting its original line of ground penetrating radars (GPR), which is meant for deep soundings and reconnaissance in rough terrain as well as shallow-depth, high-resolution imaging systems for utilities, roads, and bridges. S&S wanted a molded plastic housing, preferably a high-density polyethylene for high durability. Plastics permit molding complex parts in quantities small or large, as needed. Plastics also allow for curved, ergonomic, and visually appealing shapes nearly impossible to match in machined metal. The big learning experience for S&S was in replacing the machined steel housings for the electronic components, sort of a housing within a housing. Ove Industrial Design simplified the packaging of a ground penetrating radar system, to create a lower-priced version of the product for its manufacturer. Ove used mechanical computer-aided design/computer-aided manufacturing packages called PowerSHAPE and DUCTS from Delcam International Inc. of Windsor, Ontario, which presented S&S with a new experience.
45
Wang, Jie, Xinao Gao, Xiaoping Zhou, and Qingshen Xie. "Multi-scale Information Retrieval for BIM using Hierarchical Structure Modelling and Natural Language Processing." Journal of Information Technology in Construction 26 (July 26, 2021): 409–26. http://dx.doi.org/10.36680/j.itcon.2021.022.
Full textAbstract:
Building Information Modelling (BIM) captures numerous information the life cycle of buildings. Information retrieval is one of fundamental tasks for BIM decision support systems. Currently, most of the BIM retrieval systems focused on querying existing BIM models from a BIM database, seldom studies explore the multi-scale information retrieval from a BIM model. This study proposes a multi-scale information retrieval scheme for BIM jointly using the hierarchical structure of BIM and Natural Language Processing (NLP). Firstly, a BIM Hierarchy Tree (BIH-Tree) model is constructed to interpret the hierarchical structure relations among BIM data according to Industry Foundation Class (IFC) specification. Secondly, technologies of NLP and International Framework for Dictionaries (IFD) are employed to parse and unify the queries. Thirdly, a novel information retrieval scheme is developed to find the multi-scale information associated with the unified queries. Finally, the retrieval method proposed in this study is applied to an engineering case, and the practical results show that the proposed method is effective.
46
Fewster, Sarah. "Celebrating 200 Years of Publishing John Wiley & Sons, Inc." Publishing Research Quarterly 23, no. 3 (July 31, 2007): 161–66. http://dx.doi.org/10.1007/s12109-007-9016-0.
Full text
47
Di, Mengyang, Tamra Keeney, Emmanuelle Belanger, Orestis A. Panagiotou, and Adam J. Olszewski. "Functional Status and Therapy for Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Population-Based Study." Blood 136, Supplement 1 (November 5, 2020): 37–38. http://dx.doi.org/10.1182/blood-2020-137714.
Full textAbstract:
Background: DLBCL is a potentially curable lymphoma, yet up to 25% of older Medicare beneficiaries with DLBCL do not receive any therapy (Hamlin et al, Oncologist, 2014). Older adults with DLBCL may have vulnerabilities and require care from home health agencies. Functional impairment may compromise DLBCL therapy, but data are lacking about treatment and outcomes of home health services (HHS) recipients. There is ongoing need for accurate and efficient tools to assess function and guide therapy in geriatric patients with DLBCL, as inaccurate assessment may lead to under- and over-treatment with suboptimal outcomes. Medicare beneficiaries who receive HHS periodically undergo functional assessments using the standardized Outcome and Assessment Information Set (OASIS). OASIS scores have been recently linked to SEER-Medicare data, and can offer insights into the role of functional status in DLBCL treatment. We examined the association of functional status, measured in OASIS, and treatments and outcomes in DLBCL. Methods: From SEER-Medicare, we selected beneficiaries diagnosed with DLBCL in 2011-2015, and identified HHS recipients who had OASIS assessments within 3 months before diagnosis or treatment. OASIS instrument measures functional status as a linear score ranging from 0 to 40; higher scores represent worse functioning. We classified the scores as mild (OASIS 0-9), moderate (10-16), and severe (17-40) impairment by tertiles of the population distribution. We examined the following outcomes: receipt of therapy (including standard [RCHOP-like] and non-standard [bendamustine, rituximab monotherapy, etc.] regimens), and among treated patients: mortality, ED visit, hospitalization, and ICU admission within 30 days from first chemotherapy. We used logistic models, reporting odds ratios (OR) with 95% confidence intervals (CI). We additionally compared overall survival (OS) between groups receiving standard and non-standard regimens in each functional category using adjusted hazard ratios (aHR) derived from Cox models. All models were adjusted for age, sex, race, DLBCL stage, and comorbidity index. Results: Among 8,914 beneficiaries with DLBCL, 1,317 had OASIS assessments. Their characteristics included: median age 80 years, 46% men, 83% White, 53% stage 3/4 DLBCL. Median OASIS score was 13 (interquartile range, 7-18). Chemotherapy was administered to 63% of HHS recipients, compared with 75% of other beneficiaries (OR, 0.66; 95%CI, 0.57-0.76). HHS recipients were significantly more likely to experience 30-day ED visit, hospitalization, ICU admission, and mortality after chemotherapy (OR 1.24-1.52), and have shorter OS compared with other beneficiaries with DLBCL (7 vs 40 months, aHR, 1.55, 95% CI, 1.44-1.67; Fig. A). Severe functional impairment was associated with lower odds of receiving any therapy, as well as higher rates of acute mortality, hospitalization, and ICU admission. Patients with moderate impairment had an increased risk of 30-day ED visit and ICU admission after chemotherapy (Table). OS was worse with severe functional impairment, even after adjusting for other clinical factors (aHR, 1.64, 95% CI, 1.24-2.17; Fig. B). Functional status was not significantly associated with the use of standard or non-standard regimen, and OS was better with RCHOP-like therapy in all functional groups (aHR, 0.50-0.56, P for interaction: 0.85; Fig. C). Conclusions: In this novel population-based study using OASIS assessments to examine function as a predictor of cancer therapy, functional impairment was an independent predictor of treatment and outcomes in geriatric patients with DLBCL. We observed that a substantial proportion of patients on HHS did not receive any therapy, and worse survival in those who received attenuated regimens, independent of their functioning. Our results highlight the need for novel, less toxic strategies in this population, supporting research on emerging chemotherapy-free approaches. Clinicians should consider a dedicated functional assessment (such as a comprehensive geriatric assessment) to optimize treatment selection in DLBCL. OASIS assessments for HHS recipients are easily available to clinicians and could be incorporated into pre-chemotherapy evaluation to improve patient selection for intensive therapies, potentially avoiding under-treatment with attenuated regimens Disclosures Panagiotou: International Consulting Associates, Inc: Other: personal fees from International Consulting Associates, Inc. outside the scope of the submitted work. Olszewski:TG Therapeutics: Research Funding; Adaptive Biotechnologies: Research Funding; Spectrum Pharmaceuticals: Research Funding; Genentech, Inc.: Research Funding.
48
Dulisse, Brian, Xiaoyan Li, Julie A. Gayle, Richard L. Barron, Frank R. Ernst, Kenneth J. Rothman, Jason C. Legg, and James A. Kaye. "Clinical and Economic Burden During Hospitalizations Among Cancer Patients with Febrile Neutropenia: Evidence From U.S. Hospitals, 2007–2010." Blood 120, no. 21 (November 16, 2012): 239. http://dx.doi.org/10.1182/blood.v120.21.239.239.
Full textAbstract:
Abstract Abstract 239 Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy that often requires hospitalization. Published burden-of-illness estimates for FN-related hospitalizations were either based on clinical practice more than a decade ago (Caggiano et al Cancer 2005, Kuderer et al Cancer 2006) or derived from small samples (Schilling et al Exp Ther Med 2011). Methods: A retrospective cohort study was conducted to provide updated estimates using 2007–2010 hospital discharge data from a database maintained by Premier and containing service records of over 400 geographically diverse hospitals. It is one of the largest hospital databases in the U.S. The study population included adult patients with 1 of 6 tumor types (breast, lung, colorectal, ovarian cancers; non-Hodgkin lymphoma [NHL]; and Hodgkin lymphoma), discharge diagnoses of neutropenia (ICD-9 code 288.0x) with fever or infection, and receipt of intravenous antibiotics. The average hospitalization cost, case fatality rate, and average length of stay (LOS) associated with each patient's first FN-related hospitalization (index hospitalization) were computed with associated 95% confidence intervals (CIs) for all tumor types combined and stratified by tumor type. Detailed costs and resource utilization components within index hospitalizations were also examined and tallied. Tumor-type-specific multivariate linear regressions (for costs and LOS) and logistic regressions (for mortality) were conducted to assess the effect of infection types and comorbidities on study outcomes, adjusting for other patient and hospital characteristics. FN-related 30-day readmission rates after index hospitalizations were also estimated. All cost measures reflected actual direct costs to hospitals and were adjusted to 2010 dollars. Results: Hospitalization with FN was identified in 16,273 cancer patients. The mean (SD) age was 63 (14) years; 49% were aged ≥65 years; and 60% were female. Hospitalization costs and clinical outcomes of index hospitalizations varied by tumor type and by discharge status (Table). For all tumor types combined, 19% of patients were treated in an intensive care unit (ICU) setting during index hospitalizations, with average LOS of 5.2 days spent in ICU. The estimated models identified certain infection types and comorbidities as potential risk factors for inpatient mortality and predictors of higher economic burden. Of note, breast cancer patients with diagnosed septicemia/bacteremia (N=656) had average costs that were $5,664 (95% CI: $4,233–$7,095) higher than those with other infections (N=2,623), average LOS that was 1.7 days (95% CI: 1.0–2.3) longer, and a higher case fatality rate (risk ratio [as approximated by odds ratio]: 4.12, 95% CI: 2.6–6.5), after adjusting for other observed potential confounders. Higher average costs were also observed in NHL patients with diagnosed renal disease (N=1,263) than in those without renal disease (N=4,174) (adjusted difference: $10,408, 95% CI: $8,391–$12,425). The FN-related 30-day readmission rate after index hospitalization was 5.9% for all tumor types combined. The rate was 9.9% for NHL and 8.6% for Hodgkin lymphoma, higher than that in patients with other tumor types (2.3%–4.1%). Conclusions: FN-related hospitalizations among cancer patients are expensive, resource-intensive, and associated with considerable mortality risk. Substantial differences in the clinical and economic burden of FN exist depending on tumor types, infection types, and comorbidities. Disclosures: Dulisse: Premier healthcare alliance: Employment. Li:Amgen Inc.: Employment, Equity Ownership. Gayle:Premier healthcare alliance: Employment. Barron:Amgen Inc.: Employment, Equity Ownership. Ernst:Premier healthcare alliance, which contracted with Amgen to conduct this study.: Employment. Rothman:Dr. Rothman is an employee of RTI Health Solutions, an independent non-profit research organization that does work for government agencies and pharmaceutical companies.: Employment. Legg:Amgen Inc.: Employment, Equity Ownership. Kaye:RTI Health Solutions (a business unit of RTI International): Employment.
49
Schniering, J., M. Maciukiewicz, H. Gabrys, M. Brunner, C. Blüthgen, O. Distler, M. Guckenberger, T. Frauenfelder, S. Tanadini-Lang, and B. Maurer. "SAT0569 “IMAGES ARE MORE THAN PICTURES, THEY ARE DATA” [1] – EXPLORATION OF RADIOMICS ANALYSIS FOR SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1242.2–1243. http://dx.doi.org/10.1136/annrheumdis-2020-eular.928.
Full textAbstract:
Background:Interstitial lung disease (ILD) affects 60% of patients with systemic sclerosis (SSc) and is the primary cause of death. Medical imaging is an integral part of the routine work-up for diagnosis and monitoring of SSc-ILD and includes high-resolution computed tomography (HRCT). Radiomics is a novel research area that describes the in-depth analysis of tissue phenotypes in medical images with computational retrieval of quantitative, mineable metadata appropriate for statistical analyses.Objectives:To explore the performance of HRCT-derived radiomic features for the assessment of SSc-associated ILD (i.e. diagnosis, staging, and lung function).Methods:Radiomics analysis was performed on HRCT scans from 98 SSc patients, including n=33 SSc patients without ILD, n=33 with limited and n=32 with extensive ILD as defined by 0%, <20% and ≥20% visual extent of fibrosis on HRCT, respectively. Following semi-automated segmentation of lung tissue on 3D reconstructed HRCT scans, 1386 radiomic features, including 17 intensity, 137 texture, and 1232 wavelet features were extracted using the in-house developed software Z-Rad (Python 2.7). In order to identify robust features, we conducted intra- and inter-reader correlation analysis (ICC) in a subgroup of patients. Only features with good reproducibility (ICC ≥ 0.75) entered subsequent analyses. We applied the Wilcoxon test, followed by Receiver Operating Characteristic ROC) curve analyses, to identify features significantly different between a) ILD and non-ILD and b) limited vs. extensive ILD patients. Spearman rank correlation was performed to reveal significant associations of radiomic features from a) and b) with lung function as measured by percentage of predicted forced vital capacity (FVC% predicted).Results:In total, 1355/1386 radiomic features passed the test of robustness and were eligible for further, exploratory analyses. Radiomic features with good performance (area under the ROC curve (AUC) ≥ 0.7 and p-value ≤ 0.05) were considered as potential candidate discriminators. Under this criterion, we identified 288/1355 (21.3%) radiomic features that were significantly different between ILD and non-ILD patients and 409/1355 (30.2%) features that significantly discriminated between limited and extensive ILD (Fig. 1). For diagnosis, the texture featuredependence count entropywas the top parameter to distinguish ILD patients from healthy controls (AUC = 0.89, p = 1.83x10-10), whereas for staging the wavelet featureHHH long run high grey level emphasisproved to be best suited to separate limited from extensive ILD (AUC = 0.88, p = 7.76x10-9).Fig 1.Correlation analysis of the most significant (best performing) discriminative radiomic features with lung function revealed a significant negative correlation ofdependence count entropy(rho = -0.51, p = 9.89x10-8) andHHH long run high grey level emphasis(rho = -0.51, p = 1.73x10-5) with FVC% predicted.Conclusion:Our study adds novelty to the field of SSc-ILD showing that radiomic features have great potential as quantitative imaging biomarkers for diagnosis and staging of SSc-ILD and that they may reflect lung function. As the next step, we are planning to build predictive models, using machine learning, for diagnosis, staging, and lung function and validate them in external patient cohorts. If validated such models will pave the way for computer-aided management in SSc-ILD and thus improve patients’ outcome.References:[1]Gillies, R. J., Kinahan, P. E. & Hricak, H. Radiomics: Images Are More than Pictures, They Are Data. Radiology 278, 563-577, doi:10.1148/radiol.2015151169 (2016).Disclosure of Interests:Janine Schniering: None declared, Malgorzata Maciukiewicz: None declared, Hubert Gabrys: None declared, Matthias Brunner: None declared, Christian Blüthgen: None declared, Oliver Distler Grant/research support from: Grants/Research support from Actelion, Bayer, Boehringer Ingelheim, Competitive Drug Development International Ltd. and Mitsubishi Tanabe; he also holds the issued Patent on mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143)., Consultant of: Consultancy fees from Actelion, Acceleron Pharma, AnaMar, Bayer, Baecon Discovery, Blade Therapeutics, Boehringer, CSL Behring, Catenion, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, GSK, Glenmark Pharmaceuticals, Inventiva, Italfarmaco, iQvia, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Roche, Sanofi and UCB, Speakers bureau: Speaker fees from Actelion, Bayer, Boehringer Ingelheim, Medscape, Pfizer and Roche, Matthias Guckenberger: None declared, Thomas Frauenfelder: None declared, Stephanie Tanadini-Lang: None declared, Britta Maurer Grant/research support from: AbbVie, Protagen, Novartis, congress support from Pfizer, Roche, Actelion, and MSD, Speakers bureau: Novartis
50
Brune, James N., and Abdolrasool Anooshehpoor. "Foam Rubber Modeling of the El Centro Terminal Substation Building." Earthquake Spectra 7, no. 1 (February 1991): 45–79. http://dx.doi.org/10.1193/1.1585612.
Full textAbstract:
Results from a layered foam rubber model of soil and the structure (3-D) of the El Centro Terminal Substation building, site of the well known recording of the 1940 El Centro earthquake, indicate that the response of the foundation for frequencies above 4 Hz is as much as a factor of 3 lower than the free-field response amplitude. To validate the modeling technique with sample structure, we use the formulation for calculating theoretical responses of Wong and Luco (1977). Two-dimensional computer model results by Shannon and Wilson, Inc. and Agbabian Associates (1980), gave a response amplitude in the building about a factor of 2 lower than the response amplitude of the free-field for frequencies above 1.5 Hz. Foam rubber modeling shows that at higher frequencies most of the reduction in response is due to the energy being scattered by the shape of the rigid foundation rather than its inertial mass. Under the assumption that most of the energy was vertically incident SH, the free-field peak acceleration during the May 18, 1940 El Centro earthquake was about 50% higher than recorded on the 1940 accelerogram. The transfer function is very similar in shape to the weighting function used by Munguia and Brune (1984), to match synthetic accelerograms with the 1940 El Centro earthquake, suggesting that much of the relative deficit in high frequency energy was a result of soil-structure interaction rather than a source effect.